PainReform (PRFX) Competitors $2.24 +0.08 (+3.70%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$2.07 -0.17 (-7.41%) As of 04/1/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. PHIO, CHRO, GLTO, DWTX, AIMD, BGXX, ADXN, OBSV, BCLI, and ONCOShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Phio Pharmaceuticals (PHIO), Chromocell Therapeutics (CHRO), Galecto (GLTO), Dogwood Therapeutics (DWTX), Ainos (AIMD), Bright Green (BGXX), Addex Therapeutics (ADXN), ObsEva (OBSV), Brainstorm Cell Therapeutics (BCLI), and Onconetix (ONCO). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Phio Pharmaceuticals Chromocell Therapeutics Galecto Dogwood Therapeutics Ainos Bright Green Addex Therapeutics ObsEva Brainstorm Cell Therapeutics Onconetix PainReform (NASDAQ:PRFX) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking. Do institutionals and insiders believe in PRFX or PHIO? 37.3% of PainReform shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 34.4% of PainReform shares are held by insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate PRFX or PHIO? PainReform currently has a consensus price target of $8.00, indicating a potential upside of 257.14%. Phio Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 225.20%. Given PainReform's higher probable upside, equities research analysts clearly believe PainReform is more favorable than Phio Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer PRFX or PHIO? In the previous week, PainReform's average media sentiment score of 1.87 beat Phio Pharmaceuticals' score of 0.93 indicating that PainReform is being referred to more favorably in the media. Company Overall Sentiment PainReform Very Positive Phio Pharmaceuticals Positive Does the MarketBeat Community believe in PRFX or PHIO? Phio Pharmaceuticals received 34 more outperform votes than PainReform when rated by MarketBeat users. However, 75.00% of users gave PainReform an outperform vote while only 63.79% of users gave Phio Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPainReformOutperform Votes375.00% Underperform Votes125.00% Phio PharmaceuticalsOutperform Votes3763.79% Underperform Votes2136.21% Which has more volatility & risk, PRFX or PHIO? PainReform has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Which has higher valuation & earnings, PRFX or PHIO? Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPainReformN/AN/A-$9.34M-$147.33-0.02Phio PharmaceuticalsN/AN/A-$10.83M-$10.92-0.11 Is PRFX or PHIO more profitable? Phio Pharmaceuticals' return on equity of -134.57% beat PainReform's return on equity.Company Net Margins Return on Equity Return on Assets PainReformN/A -450.64% -241.33% Phio Pharmaceuticals N/A -134.57%-108.39% SummaryPhio Pharmaceuticals beats PainReform on 8 of the 14 factors compared between the two stocks. Remove Ads Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.96M$6.76B$5.54B$7.86BDividend YieldN/A2.80%5.35%4.04%P/E Ratio-0.027.0923.4018.67Price / SalesN/A199.58369.3087.31Price / CashN/A65.6738.1634.64Price / Book0.025.966.624.09Net Income-$9.34M$142.11M$3.20B$246.93M7 Day Performance-9.68%-7.58%-5.00%-3.16%1 Month Performance-28.89%-12.54%-1.57%-6.74%1 Year Performance-67.63%-13.53%8.66%-0.49% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform2.4965 of 5 stars$2.24+3.7%$8.00+257.1%-68.4%$1.96MN/A-0.024Upcoming EarningsPositive NewsGap UpPHIOPhio Pharmaceuticals2.61 of 5 stars$1.30+0.8%$4.00+207.7%-79.5%$8.95MN/A-0.1210Upcoming EarningsCHROChromocell TherapeuticsN/A$1.48-5.7%N/A-43.7%$8.92MN/A0.004Gap DownGLTOGalecto3.0372 of 5 stars$6.70+9.8%$10.00+49.3%-84.9%$8.82MN/A-0.3540Short Interest ↑Gap UpHigh Trading VolumeDWTXDogwood TherapeuticsN/A$6.47+2.2%N/AN/A$8.62MN/A-0.995Earnings ReportGap UpAIMDAinos0.4978 of 5 stars$0.54+1.7%N/A-57.4%$8.32M$20,729.00-0.3340BGXXBright GreenN/A$0.04+16.2%N/AN/A$8.22MN/A-0.722ADXNAddex Therapeutics2.6914 of 5 stars$7.69+0.3%$30.00+290.4%-43.1%$8.05M$556,045.00-22.6030Short Interest ↓Gap UpOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastBCLIBrainstorm Cell Therapeutics3.8212 of 5 stars$1.37-2.8%$30.00+2,089.8%-89.3%$7.81MN/A-0.2940Earnings ReportUpcoming EarningsNews CoverageGap UpONCOOnconetix0.5774 of 5 stars$0.12-6.4%N/A-98.8%$7.73M$1.87M0.0012High Trading Volume Remove Ads Related Companies and Tools Related Companies PHIO Competitors CHRO Competitors GLTO Competitors DWTX Competitors AIMD Competitors BGXX Competitors ADXN Competitors OBSV Competitors BCLI Competitors ONCO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredOil Surge Predicted... But Are You Ready?Do you own oil and gas stocks? Or are you thinking about buying some? But it's NOT oil stocks, futures, or ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRFX Stock Free PRFX Stock Alerts